RCKT ROCKET PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1281895 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY93.3%
TTM EPS YoY93.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-5.0%
ROA-4.1%
ROIC (approx.)-60.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.09x
Current ratio7.26x
Interest coverage-100.61x
Cash quality & payout
Operating cash flow / net income9.84x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $142.01M | $171.24M |
| SG&A expense | $86.50M | $101.96M |
| Operating income | -$231.75M | -$273.20M |
| Interest expense | $1.89M | $1.89M |
| Pretax income | -$223.12M | -$258.75M |
| Income tax | $0 | $0 |
| Net income | -$223.12M | -$258.75M |
| EBITDA | -$222.85M | -$266.00M |
| EPS (basic) | -2.01 | -2.73 |
| EPS (diluted) | -2.01 | -2.73 |
| Weighted avg. shares (diluted) | 111.12M | 94.81M |
| Balance sheet | ||
| Cash & equivalents | $77.56M | $165.00M |
| Short-term investments | $111.37M | $208.70M |
| Inventory | $0 | — |
| Current assets | $192.73M | $378.18M |
| PP&E, net | $28.17M | $36.79M |
| Goodwill | $39.15M | $39.15M |
| Intangibles | $25.15M | $25.15M |
| Total assets | $330.45M | $527.70M |
| Current liabilities | $30.21M | $40.68M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $53.23M | $64.47M |
| Shareholders' equity | $277.22M | $463.23M |
| Net debt | -$77.56M | — |
| Shares outstanding | 108.32M | 106.45M |
| Cash flow statement | ||
| Operating cash flow | -$190.01M | -$209.72M |
| Capital expenditure | $440,000 | $5.86M |
| Free cash flow | -$190.45M | -$215.59M |
| Investing cash flow | $103.77M | $131.71M |
| Financing cash flow | $148,000 | $185.74M |
| Depreciation & amortization | $8.90M | $7.20M |
| Stock-based compensation | $37.06M | $43.92M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.